MIV 711
Alternative Names: MIV-711Latest Information Update: 30 Apr 2024
At a glance
- Originator Medivir AB
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Osteoporosis therapies; Small molecules
- Mechanism of Action Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Osteoarthritis
Highest Development Phases
- Phase II Osteoarthritis
- Preclinical Legg-Calve-Perthes disease
- Discontinued Bone metastases; Osteoporosis